NICE does not recommend Stelara for Psoriatic Arthritis - Janssen
The National Institute for Health and Clinical Excellence (NICE) concluded in final draft guidance that Stelara (ustekinumab) from Janssen is not a cost-effective treatment option for patients with Psoriatic Arthritis after findings that the most plausible incremental cost-effectiveness ratio (ICER) for the drug is likely to exceed �30,000 per quality-adjusted life year (QALY) gained. NICE accepted that ustekinumab is clinically effective compared with conventional DMARD treatment but concluded that ustekinumab appeared less effective than TNF alpha inhibitors (e.g. Remicade, Humira and Enbrel).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.